EANM 2026: Zereau at Booth 321 – hall X3. Is Our Infrastructure Ready for the Growth of Nuclear Medicine?

Next week, the nuclear medicine community comes together in Vienna for EANM’26.

Radioligand therapy is expanding. New radiopharmaceuticals are moving through clinical development. Alpha therapies are gaining momentum. Patient access is increasing, and hospitals across Europe are preparing for further growth.

The EANM programme reflects that development. This year’s discussions range from the emerging alpha era and new radiopharmaceuticals to a European policy symposium specifically addressing Radioligand Therapy in Europe: Regulation, Readiness and Patient Access.

The word readiness is particularly interesting to us.

Bringing more radioligand therapies to patients requires progress across the entire treatment ecosystem: isotope availability, regulatory approval, clinical capacity, trained staff, hospital infrastructure – and the safe management of what leaves the patient.

Each of these brings its own challenges. Radioactive wastewater management is one part of that equation, but an increasingly relevant one as treatment numbers grow and new radionuclides enter clinical practice.

Because every additional treatment also means something very practical: hospitals need to manage the radioactive excreta that patients produce afterwards.

More treatments also mean more radioactive excreta

After administration, part of a radiopharmaceutical leaves the patient through urine and other excreta. Quite quickly actually.

As treatment numbers increase, so does the amount of radioactive wastewater that hospitals need to manage.

Traditionally, the answer has been relatively straightforward: collect wastewater in decay tanks, store it and discharge it after sufficient radioactive decay. That works. But scaling nuclear medicine is increasingly exposing its limitations.

Decay tanks require space, construction work, dedicated piping and considerable investment. Expanding treatment capacity may therefore also require expanding wastewater infrastructure – sometimes in hospitals where additional space simply does not exist.

And the next generation of therapies makes the question even more relevant. Lu-177 is expanding rapidly. Other radionuclides are emerging. Alpha emitters such as Ac-225 introduce different decay characteristics, ecotoxicology risks and other waste-management considerations.

If nuclear medicine is changing, should the infrastructure around it remain the same?

What if we manage radioactivity before we manage water?

We bring the solutions to Vienna.

For Zereau, this will be our fifth EANM. We are no longer introducing a new concept. Source-based filtration is proven technology, implemented in hospitals across Europe.

In Vienna, we will present our latest insights and technical solutions for the different wastewater challenges nuclear medicine departments face today.

For radioligand therapy, our Toilet Filter System and Urine FilterBOX provide a compact, plug-and-play solution for capturing radionuclides directly from patient excreta or urine. They can serve an individual treatment room or a shared toilet facility, allowing hospitals to start RLT without extensive wastewater infrastructure – or to expand existing treatment capacity without immediately expanding their decay tank capacity.

Where multiple wastewater streams need to be managed centrally, our Hybrid Solution combines source-based filtration with compact, central collection and decay, providing a practical alternative to relying on large-volume decay storage alone.

For nuclear medicine diagnostics, we introduce our Urine Decay System: smart urine-separation toilets combined with short-term decay and controlled discharge, without the need for conventional decay tanks.

Individual or central. Therapy or diagnostics. Filtration, decay or a combination of both.

Practical, compact and designed to scale with nuclear medicine.

At EANM’26, you can visit us at Booth 321 – hall X3. We look forward to sharing what we have learned over the past five years – and, more importantly, discussing what could work for your department.

Nuclear medicine is scaling. Its infrastructure needs to scale with it. See you in Vienna.